BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 27277844)

  • 1. Tanshinone IIA decreases the protein expression of EGFR, and IGFR blocking the PI3K/Akt/mTOR pathway in gastric carcinoma AGS cells both in vitro and in vivo.
    Su CC; Chiu TL
    Oncol Rep; 2016 Aug; 36(2):1173-9. PubMed ID: 27277844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tanshinone IIA protects against myocardial ischemia reperfusion injury by activating the PI3K/Akt/mTOR signaling pathway.
    Li Q; Shen L; Wang Z; Jiang HP; Liu LX
    Biomed Pharmacother; 2016 Dec; 84():106-114. PubMed ID: 27643552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tanshinone IIA Affects Autophagy and Apoptosis of Glioma Cells by Inhibiting Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway.
    Ding L; Ding L; Wang S; Wang S; Wang W; Wang W; Lv P; Lv P; Zhao D; Zhao D; Chen F; Chen F; Meng T; Meng T; Dong L; Dong L; Qi L; Qi L
    Pharmacology; 2017; 99(3-4):188-195. PubMed ID: 27889779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salidroside induces apoptosis and protective autophagy in human gastric cancer AGS cells through the PI3K/Akt/mTOR pathway.
    Rong L; Li Z; Leng X; Li H; Ma Y; Chen Y; Song F
    Biomed Pharmacother; 2020 Feb; 122():109726. PubMed ID: 31918283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tanshinone IIA inhibits gastric carcinoma AGS cells by decreasing the protein expression of VEGFR and blocking Ras/Raf/MEK/ERK pathway.
    Su CC
    Int J Mol Med; 2018 Apr; 41(4):2389-2396. PubMed ID: 29393362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanshinone IIA inhibits gastric carcinoma AGS cells through increasing p-p38, p-JNK and p53 but reducing p-ERK, CDC2 and cyclin B1 expression.
    Su CC
    Anticancer Res; 2014 Dec; 34(12):7097-110. PubMed ID: 25503137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tanshinone IIA can inhibit MiaPaCa‑2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways.
    Su CC
    Oncol Rep; 2018 Nov; 40(5):3102-3111. PubMed ID: 30226540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tanshinone IIA enhances the inhibitory effect of imatinib on proliferation and motility of acute leukemia cell line TIB‑152 in vivo and in vitro by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Teng Z; Xu S; Lei Q
    Oncol Rep; 2020 Feb; 43(2):503-515. PubMed ID: 31894340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanshinone IIA inhibits human gastric carcinoma AGS cell growth by decreasing BiP, TCTP, Mcl‑1 and Bcl‑xL and increasing Bax and CHOP protein expression.
    Su CC
    Int J Mol Med; 2014 Dec; 34(6):1661-8. PubMed ID: 25270224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tanshinone I attenuates the malignant biological properties of ovarian cancer by inducing apoptosis and autophagy via the inactivation of PI3K/AKT/mTOR pathway.
    Zhou J; Jiang YY; Chen H; Wu YC; Zhang L
    Cell Prolif; 2020 Feb; 53(2):e12739. PubMed ID: 31820522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antitumor natural product tanshinone IIA inhibits protein kinase C and acts synergistically with 17-AAG.
    Lv C; Zeng HW; Wang JX; Yuan X; Zhang C; Fang T; Yang PM; Wu T; Zhou YD; Nagle DG; Zhang WD
    Cell Death Dis; 2018 Feb; 9(2):165. PubMed ID: 29416003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tanshinone IIA induces mitochondria dependent apoptosis in prostate cancer cells in association with an inhibition of phosphoinositide 3-kinase/AKT pathway.
    Won SH; Lee HJ; Jeong SJ; Lee HJ; Lee EO; Jung DB; Shin JM; Kwon TR; Yun SM; Lee MH; Choi SH; Lü J; Kim SH
    Biol Pharm Bull; 2010; 33(11):1828-34. PubMed ID: 21048307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tanshinone IIA affects the malignant growth of Cholangiocarcinoma cells by inhibiting the PI3K-Akt-mTOR pathway.
    Liu H; Liu C; Wang M; Sun D; Zhu P; Zhang P; Tan X; Shi G
    Sci Rep; 2021 Sep; 11(1):19268. PubMed ID: 34588580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Ag-1031 on apoptosis in gastric cancer AGS cells and its effects on the PI3K/AKT/mTOR signaling pathway.
    Dai J; Liu D; Chen L; Sun L
    Biotechnol Lett; 2020 Nov; 42(11):2447-2452. PubMed ID: 32651704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pectolinarigenin Induced Cell Cycle Arrest, Autophagy, and Apoptosis in Gastric Cancer Cell via PI3K/AKT/mTOR Signaling Pathway.
    Lee HJ; Venkatarame Gowda Saralamma V; Kim SM; Ha SE; Raha S; Lee WS; Kim EH; Lee SJ; Heo JD; Kim GS
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30096805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
    Li X; Li Z; Li X; Liu B; Liu Z
    BMC Cancer; 2017 May; 17(1):357. PubMed ID: 28532456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T; Wanek T; Pflegerl P; Jaeger-Lansky A; Hoeflmayer D; Strommer S; Kuntner C; Wrba F; Werzowa J; Hejna M; Müller M; Langer O; Wacheck V
    Clin Cancer Res; 2011 Aug; 17(16):5322-32. PubMed ID: 21712451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mefloquine effectively targets gastric cancer cells through phosphatase-dependent inhibition of PI3K/Akt/mTOR signaling pathway.
    Liu Y; Chen S; Xue R; Zhao J; Di M
    Biochem Biophys Res Commun; 2016 Feb; 470(2):350-355. PubMed ID: 26780727
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Qian Y; Yan Y; Lu H; Zhou T; Lv M; Fang C; Hou J; Li W; Chen X; Sun H; Li Y; Wang Z; Zhao N; Gu Y; Ding Y; Liu Y
    Anticancer Agents Med Chem; 2019; 19(14):1754-1761. PubMed ID: 31364518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.